
Pancreas transplantation is currently the only therapy that can reliably establish long-term glucose control independent of exogenous insulin administration. Since the introduction of pancreas transplantation nearly sixty years ago, outcomes have steadily improved in the ensuing decades secondary to a marked decrease in early technical allograft failures. This positive trend in outcomes is the consequence of advances in donor selection and management, organ retrieval and preservation, recipient selection and overall medical care, surgical techniques and perioperative management, diagnostic and interventional methodology, immunosuppression medications and strategies, and anti-infective prophylaxis. In this review, surgical techniques for pancreas allograft implantation will be described, with a focus on the prevention, identification, and management of technical complications. Early post-operative management during the index hospitalization will also be discussed with an emphasis on anticipating and managing the sequelae of long-term diabetes that may complicate the immediate post-operative course.
Maintenance immunosuppression for pancreas transplantation has been largely derived from kidney transplant practice. The combination of a calcineurin inhibitor (CNI), mycophenolate and corticosteroids remains the backbone of immunosuppression in pancreas transplantation. Although this regimen achieves very low rejection rates and excellent short-term survival, progressive CNI-induced nephrotoxicity, β-cell injury, and cardiovascular and metabolic adverse effects carry significant long-term consequences among pancreas transplant recipients. This review examines the utility of CNI withdrawal or minimization by utilizing belatacept and/or mammalian target of rapamycin (mTOR) inhibitors, and the utility of steroid-sparing regimens in pancreas transplantation. Belatacept is associated with an increased risk of acute rejection when used in the setting of CNI withdrawal but can be effective when added to a low-dose CNI regimen. Late conversion while maintaining a low-dose CNI is associated with better allograft survival and lower rejection rates. Steroid withdrawal can be successful in the low immunologic risk population when paired with effective adjunct maintenance immunosuppression. mTOR inhibitors are associated with higher drug intolerance but may confer benefits depending on the timing, immunologic risk and infection status. Outcomes are determined by the immunosuppression that remains rather than the agent that was withdrawn. Pancreas allograft survival is impacted by the occurrence and severity of rejection regardless of the combination of immunosuppression that is utilized. An individualized approach guided by transplant type, immunologic risk, timing of intervention, and cardiometabolic and infectious risks is of utmost importance in managing immunosuppression among pancreas transplant recipients.
Antibody-mediated rejection (ABMR) is a leading cause of late graft loss, and current therapies act almost exclusively on the effector arm of the alloimmune response. This review examines three classes of regulatory cell from innate and adaptive lineages and the stages of the ABMR response at which each acts, in order to assess their potential as therapeutic targets. CD4⁺ Tregs constrain alloimmune priming through CTLA4 dependent costimulatory blockade, cytokine-mediated suppression, and competition for IL-2. CXCR5⁺CD8⁺ antibody-suppressor cells directly eliminate donor-reactive IgG⁺ B cells in murine models. T follicular regulatory (Tfr) cells restrain germinal center reactions and alloantibody generation, and their loss produces enhanced, more pathogenic donor-specific antibody (DSA). Notably, Tfr regulation is initiated early in T-B interactions, Tfr expansion physiologically lags that of Tfh cells, and Tfr numbers are reduced in chronic ABMR. Regulatory B cells and myeloid-derived suppressor cells remain comparatively unexplored in ABMR, and the latter carry a risk of profibrotic differentiation under chronic inflammatory conditions. Regulatory cell populations act predominantly during the early phases of the alloimmune response. Their therapeutic utility in ABMR is therefore likely to be constrained by timing, and to lie in the prevention of de novo DSA rather than the reversal of established rejection.
Raman spectroscopy and surface-enhanced Raman scattering (SERS) are analytical techniques for non-invasive assessment of kidney transplant health. By producing molecular fingerprints through inelastic light scattering, they’re able to detect biochemical changes associated with graft injury, immune activation, and other relevant pathophysiological changes. This review synthesizes current evidence of Raman-based techniques across three key domains in kidney transplantation: transplant monitoring, donor organ assessment, and evaluation of alloreactive immune activation. Recent studies demonstrate that SERS can be applied to biofluids and can accurately distinguish between transplant states. Additionally, Raman-based analyses of donor-derived samples show potential for predicting transplant outcomes and identifying viable organs despite high-risk features. It has also been shown to differentiate between activated and non-activated T lymphocytes. Raman spectroscopy and SERS represent powerful, non-invasive approaches that have the potential to reduce the reliance on invasive biopsy.
Over the past two decades, pancreas transplantation in the United States has experienced a marked and persistent decrease in activity at the national and programmatic levels. Recently, significant increases in donation after circulatory death cases and the use of perfusion technologies have culminated in a major threat to training the future pancreas transplant workforce. Although pancreas transplantation remains the only established surgical therapy providing long-term insulin independence for people managing insulin dependent diabetes, declining procedure numbers have undermined surgical and medical training opportunities in this technically complex field. The effect of less training is evident in both the recovery and transplant settings. This paper examines national trends in pancreas transplant activity, the workforce in place, and fellowship training exposure. Through this lens we explore the systemic drivers and implications for the future pancreas transplant workforce and future patient access to pancreas transplantation.